Anderson et al30 evaluated BC patients between 40 and 45 years of age and, while emphasizing the validity of post-treatment AMH as a marker for ovarian reserve, showed that AMH0 was a significant predictor of AMH after 30 months. Here, AMH is linked to breast cancer.